Table 4 Association between CD147 plasma membrane expression, alone or co-expressed with MCT1, and the clinical-pathological parameters

Age

0.498

0.583

0.308

 >51

48

23 (47.9)

21 (43.8)

18 (37.5)

 ≤51

37

15 (40.5)

14 (37.8)

10 (27.0)

Gender

0.577

0.523

0.680

 Female

33

16 (48.5)

15 (45.5)

10 (30.3)

 Male

52

22 (42.3)

29 (38.5)

19 (34.6)

Race

0.562

0.976

0.511

 Caucasian

63

27 (42.9)

26 (41.3)

22 (34.9)

 Not Caucasian

22

11 (50.0)

9 (40.9)

6 (27.3)

Local

0.936

0.751

0.432

 Lower extremities

63

28 (44.4)

25 (39.7)

19 (30.2)

 Upper extremities

23

10 (43.5)

10 (43.5)

9 (39.1)

Cell lineage

0.878

0.694

0.071

 Fibroblastic/myofibroblastic

28

13 (46.4)

12 (42.9)

12 (42.9)

 Smooth muscle

17

6 (35.3)

6 (35.3)

5 (29.4)

 Lipogenic

17

7 (41.2)

5 (29.4)

1 (5.9)

 Peripheral nerve

7

3 (42.9)

3 (42.9)

2 (28.6)

 Miscellaneous

17

9 (52.9)

9 (52.9)

8 (47.1)

Cellular pleomorphism

0.083

0.071

0.002

 Absence of pleomorphic cells

54

20 (37.0)

18 (33.3)

11 (20.4)

 Presence of pleomorphic cells

32

18 (56.2)

17 (53.1)

17 (53.1)

Grade

0.076

0.016

0.026

 Low grade (I)

19

5 (26.3)

3 (15.8)

2 (10.5)

 High grade (II e III)

67

33 (49.3)

32 (47.8)

26 (38.8)

Disease progression

0.020

0.016

0.070

 No

25

6 (24.0)

5 (20.0)

4 (16.0)

 Yes

56

29 (51.8)

27 (48.2)

21 (37.5)

Disease recurrence

0.949

0.847

0.840

 Absent

48

21 (43.8)

19 (39.6)

15 (31.2)

 Present

36

16 (44.4)

15 (41.7)

12 (33.3)

Metastasis

0.295

0.090

0.593

 Absent

44

17 (38.6)

14 (31.8)

13 (29.5)

 Present

40

20 (50.0)

20 (50.0)

14 (35.0)